Standing Order

Vertical

Biotech

Metabolic medicine and the longevity bet

The GLP-1 obesity supercycle is one of the most-cited themes of the decade, with knock-on effects rippling across food, devices, and health systems. Behind it sits a deeper bet on metabolic disease and longevity.

We track the incumbents and the clinical-stage challengers chasing them.

NVSVRTXAMGNLLYAZNREGNNVOGILDPFEMRNA
Sort

33 companies

Alnylam Pharmaceuticals, Inc.ALNY
Market cap$19B
Conviction5 / 5
RNA therapeuticsMetabolic disease
Read profile
Novartis AGNVS
Market cap$284B
Conviction5 / 5
RadiopharmaceuticalsRNA therapeutics
Read profile
97
Vertex Pharmaceuticals IncorporatedVRTX
Market cap$131B
Conviction5 / 5
Gene editing
Read profile
Amgen Inc.AMGN
Market cap$236B
Conviction5 / 5
GLP-1Obesity
Read profile
99
Eli Lilly and CompanyLLY
Market cap$1.2T
Conviction5 / 5
GLP-1Obesity
Read profile
Lantheus Holdings, Inc.LNTH
Market cap$6.7B
Conviction4 / 5
Radiopharmaceuticals
Read profile
96
AstraZeneca PLCAZN
Market cap$270B
Conviction4 / 5
Metabolic disease
Read profile
Regeneron Pharmaceuticals, Inc.REGN
Market cap$94B
Conviction4 / 5
Metabolic disease
Read profile
89
Madrigal Pharmaceuticals, Inc.MDGL
Market cap$8.8B
Conviction4 / 5
Metabolic diseaseObesity
Read profile
Bachem Holding AGBANB
Market cap$6.8B
Conviction4 / 5
GLP-1Metabolic disease
Read profile
99
Novo Nordisk A/SNVO
Market cap$126B
Conviction4 / 5
GLP-1Obesity
Read profile
91
CRISPR Therapeutics AGCRSP
Market cap$3.8B
Conviction4 / 5
Gene editing
Read profile
91
Tempus AI, Inc.TEM
Market cap$9.6B
Conviction4 / 5
AI drug discovery
Read profile
80
Telix Pharmaceuticals LimitedTLX
Market cap$2.8B
Conviction4 / 5
Radiopharmaceuticals
Read profile
Xaira Therapeutics, Inc.Private
Market cap—
Conviction4 / 5
AI drug discovery
Read profile
Legend Biotech CorporationLEGN
Market cap$3.0B
Conviction3 / 5
Cell therapy
Read profile
80
Kymera Therapeutics, Inc.KYMR
Market cap$9.8B
Conviction3 / 5
Targeted protein degradation
Read profile
Schrödinger, Inc.SDGR
Market cap$1.5B
Conviction3 / 5
AI drug discovery
Read profile
Gilead Sciences, Inc.GILD
Market cap$206B
Conviction3 / 5
Metabolic disease
Read profile
Illumina, Inc.ILMN
Market cap$29B
Conviction3 / 5
AI drug discovery
Read profile
84
Pfizer Inc.PFE
Market cap$156B
Conviction3 / 5
Obesity
Read profile
Isomorphic Labs LimitedPrivate
Market cap—
Conviction3 / 5
AI drug discovery
Read profile
95
Viking Therapeutics, Inc.VKTX
Market cap$3.2B
Conviction3 / 5
ObesityMetabolic disease
Read profile
Zealand Pharma A/SZEAL
Market cap$2.0B
Conviction3 / 5
ObesityGLP-1
Read profile
Arvinas, Inc.ARVN
Market cap$423M
Conviction3 / 5
Targeted protein degradation
Read profile
Beam Therapeutics Inc.BEAM
Market cap$2.2B
Conviction3 / 5
Gene editing
Read profile
81
Perspective Therapeutics, Inc.CATX
Market cap$91M
Conviction3 / 5
Radiopharmaceuticals
Read profile
85
Intellia Therapeutics, Inc.NTLA
Market cap$1.4B
Conviction3 / 5
Gene editing
Read profile
86
Recursion Pharmaceuticals, Inc.RXRX
Market cap$1.5B
Conviction3 / 5
AI drug discovery
Read profile
85
Moderna, Inc.MRNA
Market cap$79B
Conviction3 / 5
AI drug discovery
Read profile
Structure Therapeutics Inc.GPCR
Market cap$1.2B
Conviction2 / 5
ObesityGLP-1
Read profile
Scholar Rock Holding CorporationSRRK
Market cap$5.9B
Conviction2 / 5
Metabolic disease
Read profile
Absci CorporationABSI
Market cap$1.3B
Conviction1 / 5
AI drug discovery
Read profile